Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Multiple Myeloma 8Recurrence 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Smoldering Multiple Myeloma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Castleman Disease 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1

Interventions

Pemetrexed 5ponatinib 4pembrolizumab 4Carboplatin 4Cisplatin 3130-nm albumin-bound paclitaxel 3tetulomab tetraxetan lu-177 2pralsetinib 2osimertinib 2napabucasin 2fludarabine 2ficlatuzumab 2entinostat 2durvalumab 2atezolizumab 2Rituximab 2Paclitaxel 2Lutetium 2Irinotecan 2Immunotherapy 2Imatinib Mesylate 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2vorasidenib 1siltuximab 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Histologic Type × siltuximab × Clear all
NCT00841191 2014-05-14

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Centocor, Inc.

Phase 1/2 Completed
84 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms by Histologic Type, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡